Related Experiment Videos
Open study of teicoplanin in gram-positive infections
Abstract:
Eighteen patients with documented Gram-positive infections which included osteomyelitis, prosthetic infections, endocarditis, skin and soft tissue, and urinary tract infections were treated with teicoplanin. The organisms involved included Staphylococcus aureus (15 isolates of which six were methicillin-resistant-MRSA), Staphylococcus epidermidis (two), Streptococcus faecalis (one) and Streptococcus milleri (one). Clinical success occurred in all seven patients with skin and soft tissue Streptococcus milleri (one). Clinical success occurred in all seven patients with skin and soft tissue infections (with bacterial persistence in three out of the seven), in three patients with bacteraemia endocarditis, and in one of the three patients with chronic osteomyelitis. In four patients with prosthetic bone and joint infections, clinical improvement followed removal of prostheses. Adverse effects occurred in two patients and these included one patient with a rise in serum aspartate aminotransferase and bilirubin and one patient with a rise in blood urea, both of which returned to within normal limits on discontinuing the drug. The study showed that teicoplanin is a safe and effective antistaphylococcal agent.
Insights
Teicoplanin effectively treated Gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). This antibiotic demonstrated safety and efficacy in diverse infections like osteomyelitis and endocarditis.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Gram-positive bacterial infections pose significant therapeutic challenges.
- Antibiotic resistance, particularly methicillin-resistant Staphylococcus aureus (MRSA), necessitates effective treatment options.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of teicoplanin in patients with documented Gram-positive infections.
- To assess teicoplanin's effectiveness against various Gram-positive pathogens, including MRSA.
Main Methods:
- A cohort of eighteen patients with documented Gram-positive infections received teicoplanin treatment.
- Infections included osteomyelitis, prosthetic infections, endocarditis, skin and soft tissue, and urinary tract infections.
- Microbiological identification and susceptibility testing were performed for causative organisms.
Main Results:
- Clinical success was observed in all seven patients with skin and soft tissue infections.
- Positive outcomes were noted in three patients with bacteraemia endocarditis and one with chronic osteomyelitis.
- Teicoplanin demonstrated a favorable safety profile with only two patients experiencing transient adverse effects.
Conclusions:
- Teicoplanin is a safe and effective antistaphylococcal agent for treating various Gram-positive infections.
- The study supports teicoplanin as a viable therapeutic option, especially against MRSA.
- Further research may explore teicoplanin's role in complex infections like osteomyelitis and prosthetic joint infections.